A Novel Clinically Significant Prostate Cancer Prediction System with Multiparametric MRI and PSA: P.Z.A. Score

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Nov 23

PMID 37996859

Authors

Zongxin Chen

Jun Zhang

Di Jin

Xuedong Wei

Feng Qiu

Ximing Wang

Xiaojun Zhao

Jinxian Pu

Jianquan Hou

Yuhua Huang

Chen Huang

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to establish and validate a new diagnosis model called P.Z.A. score for clinically significant prostate cancer (csPCa).

Methods: The demographic and clinical characteristics of 956 patients were recorded. Age, prostate-specific antigen (PSA), free/total PSA (f/tPSA), PSA density (PSAD), peripheral zone volume ratio (PZ-ratio), and adjusted PSAD of PZ (aPSADPZ) were calculated and subjected to receiver operating characteristic (ROC) curve analysis. The nomogram was established, and discrimination abilities of the new nomogram were verified with a calibration curve and area under the ROC curve (AUC). The clinical benefits of P.Z.A. score were evaluated by decision curve analysis and clinical impact curves. External validation of the model using the validation set was also performed.

Results: The AUCs of aPSADPZ, age, PSA, f/tPSA, PSAD and PZ-ratio were 0.824, 0.672, 0.684, 0.715, 0.792 and 0.717, respectively. The optimal threshold of P.Z.A. score was 0.41. The nomogram displayed excellent net benefit and better overall calibration for predicting the occurrence of csPCa. In addition, the number of patients with csPCa predicted by P.Z.A. score was in good agreement with the actual number of patients with csPCa in the high-risk threshold. The validation set provided better validation of the model.

Conclusion: P.Z.A. score (including PIRADS(P), aPSADPZ(Z) and age(A)) can increase the detection rate of csPCa, which may decrease the risk of misdiagnosis and reduce the number of unnecessary biopsies. P.Z.A. score contains data that is easy to obtain and is worthy of clinical replication.

Citing Articles

Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.

Jin Y, Chen F, Xu G, Wei C, Dong C Sci Rep. 2025; 15(1):3258.

PMID: 39863696 PMC: 11762996. DOI: 10.1038/s41598-025-87311-1.

The value of adjusted PSAD in prostate cancer detection in the Chinese population.

Wang F, Fu M, Tang Y, Li J Front Oncol. 2024; 14:1462997.

PMID: 39416462 PMC: 11479861. DOI: 10.3389/fonc.2024.1462997.

Precision in prostate cancer detection: integrating prostate-specific antigen density (PSAD) and the Prostate Imaging Reporting and Data System (PI-RADS) to provide additional risk stratification for a more accurate diagnostic decision.

Hruba T, Kubas V, Franko M, Balaz V, Spurny M, Mistinova J Ir J Med Sci. 2024; 193(6):2635-2642.

PMID: 39093531 PMC: 11666638. DOI: 10.1007/s11845-024-03771-w.

References

Porcaro A, Tafuri A, Sebben M, Novella G, Processali T, Pirozzi M . Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy. World J Urol. 2019; 38(4):957-964. DOI: 10.1007/s00345-019-02830-7. View

Patel N, Lind K, Garg K, Crawford D, Werahera P, Pokharel S . Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer. Abdom Radiol (NY). 2018; 44(2):705-712. DOI: 10.1007/s00261-018-1751-5. View

Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y . Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients. BJU Int. 2016; 119(2):225-233. DOI: 10.1111/bju.13465. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Liang C, Wang Y, Ding L, Bao M, Cheng G, Shao P . A comprehensive prostate biopsy standardization system according to quantitative multiparametric MRI and PSA value: P.R.O.S.T score. World J Urol. 2022; 40(9):2245-2253. DOI: 10.1007/s00345-022-04102-3. View

Turkbey B, Rosenkrantz A, Haider M, Padhani A, Villeirs G, Macura K . Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019; 76(3):340-351. DOI: 10.1016/j.eururo.2019.02.033. View

Taira A, Merrick G, Galbreath R, Andreini H, Taubenslag W, Curtis R . Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2009; 13(1):71-7. PMC: 2834351. DOI: 10.1038/pcan.2009.42. View

Donato P, Morton A, Yaxley J, Teloken P, Coughlin G, Esler R . Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. World J Urol. 2019; 38(2):371-379. DOI: 10.1007/s00345-019-02774-y. View

Albertsen P . Prostate cancer screening and treatment: where have we come from and where are we going?. BJU Int. 2020; 126(2):218-224. DOI: 10.1111/bju.15153. View

10.

Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken P, Kyle S . Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is Ga-PSMA PET/CT guided biopsy the future?. Eur J Nucl Med Mol Imaging. 2020; 47(8):1843-1851. DOI: 10.1007/s00259-019-04620-0. View

11.

DeLong E, Delong D, Clarke-Pearson D . Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45. View

12.

Eastham J, May R, Robertson J, Sartor O, Kattan M . Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999; 54(4):709-13. DOI: 10.1016/s0090-4295(99)00213-7. View

13.

Barth B, Martini K, Skawran S, Schmid F, Rupp N, Zuber L . Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI. Eur J Radiol Open. 2021; 8:100332. PMC: 7930347. DOI: 10.1016/j.ejro.2021.100332. View

14.

Scheltema M, Chang J, Stricker P, van Leeuwen P, Nguyen Q, Ho B . Diagnostic accuracy of Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of.... BJU Int. 2019; 124 Suppl 1:42-49. DOI: 10.1111/bju.14794. View

15.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

16.

Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts M . The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021; 80(6):682-689. DOI: 10.1016/j.eururo.2021.08.002. View

17.

Chang Y, Chen R, Yang Q, Gao X, Xu C, Lu J . Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality. Oncotarget. 2017; 8(21):34836-34843. PMC: 5471015. DOI: 10.18632/oncotarget.16753. View

18.

Rodriguez Cabello M, Mendez Rubio S, Platas Sancho A, Carballido Rodriguez J . Diagnostic evaluation and incorporation of PSA density and the prostate imaging and data reporting system (PIRADS) version 2 classification in risk-nomograms for prostate cancer. World J Urol. 2022; 40(10):2439-2450. DOI: 10.1007/s00345-022-04118-9. View

19.

Zhou Z, Liang Z, Zuo Y, Zhou Y, Yan W, Wu X . Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region. Prostate. 2022; 82(5):556-565. DOI: 10.1002/pros.24302. View

20.

Kasivisvanathan V, Rannikko A, Borghi M, Panebianco V, Mynderse L, Vaarala M . MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018; 378(19):1767-1777. PMC: 9084630. DOI: 10.1056/NEJMoa1801993. View